Buy GHRP-2 10mg

GHRP-2 (Growth Hormone Releasing Peptide-2, also known as KP-102) is a synthetic hexapeptide — D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2 — classified as a first-generation growth hormone secretagogue. It acts as a potent agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), a Gαq protein-coupled receptor expressed on anterior pituitary somatotroph cells, hypothalamic neurons, and peripheral tissues including the heart and GI tract. GHS-R1a is the cognate receptor for ghrelin, the endogenous gut-derived orexigenic peptide, and GHRP-2 mimics ghrelin's GH-releasing activity with greater potency and selectivity for GH release over orexigenic effects. GHS-R1a activation by GHRP-2 triggers phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilises calcium from the endoplasmic reticulum and opens voltage-gated calcium channels, producing a rapid, transient intracellular calcium spike within somatotrophs. This calcium surge drives exocytosis of pre-formed GH secretory granules through a SNARE protein-dependent mechanism, generating the acute GH pulse characteristic of GHRP-2 administration. DAG simultaneously activates protein kinase C, further amplifying secretory output and contributing to GH1 transcriptional upregulation via PKC-mediated CREB phosphorylation. GHRP-2's GH-releasing mechanism also involves hypothalamic action. Within the arcuate nucleus and paraventricular nucleus, GHS-R1a activation by GHRP-2 inhibits somatostatin-releasing neurons, reducing somatostatin tone at the pituitary. Since somatostatin is the primary inhibitory regulator of GH secretion, its suppression dramatically amplifies the GH response to concurrent GHRH-mediated stimulation — providing the mechanistic basis for the synergistic GH output observed when GHRP-2 is co-administered with a GHRH analogue such as CJC-1295 or sermorelin. The combination of somatostatin suppression (GHRP-2) and direct pituitary cAMP/calcium stimulation (GHRH analogue) represents two orthogonal inputs converging on the same exocytotic endpoint. Despite its potent GH-releasing properties, GHRP-2 exhibits meaningful off-target GHS-R1a activity in non-pituitary tissues. Adrenal GHS-R1a activation elevates cortisol by stimulating ACTH release from the anterior pituitary via MC2-R-independent pathways, and prolactin elevation has also been documented in controlled studies. These off-target hormonal effects — approximately three to fivefold cortisol elevation above baseline at therapeutic GHRP-2 doses — distinguish GHRP-2 from the more selective ipamorelin and represent the primary tolerability limitation of this compound. Downstream IGF-1 signalling following GHRP-2-induced GH release proceeds through the standard hepatic JAK2/STAT5 pathway, generating systemic anabolic and lipolytic effects mediated by PI3K/Akt/mTORC1 and HSL activation, respectively.

GHRP-2 is best suited for experienced peptide users who prioritise maximal acute GH pulse amplitude and are willing to manage the cortisol and prolactin side effects through cycle structure and monitoring. It is particularly relevant as a component of combination protocols — paired with CJC-1295 or sermorelin — where the synergistic GH output justifies the off-target hormonal activity. Users who have found ipamorelin's GH response insufficient and seek greater magnitude stimulation may benefit from GHRP-2. It is not recommended as a standalone agent for recovery-focused applications where elevated cortisol would undermine the intended benefit. When sourcing GHRP-2, verify HPLC purity above 98% and confirm the correct hexapeptide molecular weight (604.7 g/mol) by mass spectrometry. The 10 mg vial provides ample supply for a standard research cycle. Lyophilised peptide should be white and free-flowing before reconstitution; any yellow discolouration or caking suggests degradation or inadequate lyophilisation. Reconstitute with bacteriostatic water; stored at 4°C, reconstituted GHRP-2 is stable for four to six weeks. Standard research dosing is 100–300 µg per injection, administered subcutaneously two to three times daily — typically upon waking, pre-workout, and before sleep. Fasting for at least 60–90 minutes before dosing and avoiding high-fat meals maximises GH response. When used as part of a combination with a GHRH analogue, 100 µg of GHRP-2 paired with 100 µg of CJC-1295 or sermorelin is the most common protocol. Users should monitor cortisol and prolactin at baseline and at four-week intervals during extended cycles. Cycle lengths of eight to twelve weeks followed by a four-week break help prevent receptor desensitisation.

The primary comparison point for GHRP-2 is ipamorelin — the other leading injectable GHS in this class. GHRP-2 achieves greater peak GH release per unit dose, making it the more potent option for applications requiring maximal acute GH stimulation. However, ipamorelin's near-complete selectivity for GHS-R1a on somatotrophs — with minimal cortisol and prolactin activation — makes it the superior choice for most wellness, recovery, and body composition applications where the anabolic benefits of GH/IGF-1 would be neutralised by concurrent cortisol elevation. The GHRP-2 versus ipamorelin choice fundamentally reduces to a question of whether the user requires maximum GH amplitude or optimal anabolic hormonal environment. Compared to GHRP-6 — the first-generation hexapeptide predecessor — GHRP-2 produces comparable or slightly greater GH release with less pronounced appetite stimulation. GHRP-6's intense hunger-inducing properties (a direct GHS-R1a/NPY pathway effect) limited its practical utility for many users, particularly those managing caloric intake for fat loss. GHRP-2 sits between GHRP-6 (greater appetite, similar GH release) and ipamorelin (less appetite, less GH release but cleaner hormonal profile) on the selectivity spectrum. For users with a strong performance-enhancement priority and adequate cortisol management capacity — through cycle timing, dietary approaches, or adjunct phosphatidylserine supplementation — GHRP-2 remains a highly effective secretagogue option.